Bone and Soft Tissue Sarcoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (10 December 2020) | Viewed by 30013
Special Issue Editor
Interests: clinical pharmacology; antineoplastic drugs; clinical trial; pediatric drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Sarcomas are relatively rare both in children and adults. Sarcomas are a heterogeneous category of tumors and can arise in any body district. Bone and soft tissue sarcomas are the main types of sarcoma.
Over the last few decades, there have been remarkable advances in the multimodal treatment of bone and soft tissue sarcomas. These include the introduction of adjuvant chemotherapy, establishment of guidelines for adequate surgical margins and radiotherapy, and the development of post-surgical bone and tissue reconstruction. Nevertheless, these cancers present challenges in new drug development partly because of their relative rarity and heterogeneity. However, based on recently obtained molecular data, several clinical trials are ongoing with new immunotherapeutic drugs and molecular targeted therapies.
In this Special Issue, experts in this field will review the current status of, and new approaches to, the interdisciplinary management of patients with bone and soft tissue sarcomas.
Prof. Dr. Antonio Ruggiero
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.